These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 27527089)

  • 1. Correlation of Checkerboard Synergy Testing with Time-Kill Analysis and Clinical Outcomes of Extensively Drug-Resistant Acinetobacter baumannii Respiratory Infections.
    Bremmer DN; Bauer KA; Pouch SM; Thomas K; Smith D; Goff DA; Pancholi P; Balada-Llasat JM
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6892-6895. PubMed ID: 27527089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii.
    Park GC; Choi JA; Jang SJ; Jeong SH; Kim CM; Choi IS; Kang SH; Park G; Moon DS
    Ann Lab Med; 2016 Mar; 36(2):124-30. PubMed ID: 26709259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests.
    Jean SS; Hsieh TC; Hsu CW; Lee WS; Bai KJ; Lam C
    J Microbiol Immunol Infect; 2016 Dec; 49(6):924-933. PubMed ID: 26341302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates.
    Tan TY; Ng LS; Tan E; Huang G
    J Antimicrob Chemother; 2007 Aug; 60(2):421-3. PubMed ID: 17540671
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Soudeiha MAH; Dahdouh EA; Azar E; Sarkis DK; Daoud Z
    Front Cell Infect Microbiol; 2017; 7():209. PubMed ID: 28596943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of rifampin, colistin, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter baumannii.
    Dong X; Chen F; Zhang Y; Liu H; Liu Y; Ma L
    J Antibiot (Tokyo); 2014 Sep; 67(9):677-80. PubMed ID: 25095805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose Optimization of Colistin Combinations against Carbapenem-Resistant Acinetobacter baumannii from Patients with Hospital-Acquired Pneumonia in China by Using an
    Bian X; Liu X; Chen Y; Chen D; Li J; Zhang J
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Do different interpretative methods used for evaluation of checkerboard synergy test affect the results?].
    Ozseven AG; Sesli Çetin E; Ozseven L
    Mikrobiyol Bul; 2012 Jul; 46(3):410-20. PubMed ID: 22951653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postantibiotic effects of tigecycline, colistin sulfate, and levofloxacin alone or tigecycline-colistin sulfate and tigecycline-levofloxacin combinations against Acinetobacter baumannii.
    Ozbek B; Sentürk A
    Chemotherapy; 2010; 56(6):466-71. PubMed ID: 21088399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergy against extensively drug-resistant Acinetobacter baumannii in vitro by two old antibiotics: colistin and chloramphenicol.
    Wei WJ; Yang HF
    Int J Antimicrob Agents; 2017 Mar; 49(3):321-326. PubMed ID: 28167347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii.
    Mutlu Yilmaz E; Sunbul M; Aksoy A; Yilmaz H; Guney AK; Guvenc T
    Int J Antimicrob Agents; 2012 Oct; 40(4):332-6. PubMed ID: 22831842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen.
    Shields RK; Kwak EJ; Potoski BA; Doi Y; Adams-Haduch JM; Silviera FP; Toyoda Y; Pilewski JM; Crespo M; Pasculle AW; Clancy CJ; Nguyen MH
    Diagn Microbiol Infect Dis; 2011 Jun; 70(2):246-52. PubMed ID: 21353436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Epidemiology and Drug Resistance of Acinetobacter baumannii Isolated from Hospitals in Southern Poland: ICU as a Risk Factor for XDR Strains.
    Chmielarczyk A; Pilarczyk-Żurek M; Kamińska W; Pobiega M; Romaniszyn D; Ziółkowski G; Wójkowska-Mach J; Bulanda M
    Microb Drug Resist; 2016 Jun; 22(4):328-35. PubMed ID: 26745326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of colistin plus sulbactam against extensive-drug-resistant Acinetobacter baumannii by checkerboard method.
    Thamlikitkul V; Tiengrim S
    J Med Assoc Thai; 2014 Mar; 97 Suppl 3():S1-6. PubMed ID: 24772574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vitro Activity of Various Antibiotics in Combination with Tigecycline Against Acinetobacter baumannii: A Systematic Review and Meta-Analysis.
    Li J; Yang X; Chen L; Duan X; Jiang Z
    Microb Drug Resist; 2017 Dec; 23(8):982-993. PubMed ID: 28437233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia.
    Liu CP; Shih SC; Wang NY; Wu AY; Sun FJ; Chow SF; Chen TL; Yan TR
    J Microbiol Immunol Infect; 2016 Dec; 49(6):934-940. PubMed ID: 25553994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model.
    Fan B; Guan J; Wang X; Cong Y
    PLoS One; 2016; 11(6):e0157757. PubMed ID: 27315107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of colistin heteroresistance in Acinetobacter baumannii from blood and respiratory isolates.
    Srinivas P; Hunt LN; Pouch SM; Thomas K; Goff DA; Pancholi P; Balada-Llasat JM; Bauer KA
    Diagn Microbiol Infect Dis; 2018 Jun; 91(2):194-198. PubMed ID: 29482871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: A survey study.
    Zilberberg MD; Kollef MH; Shorr AF
    J Hosp Med; 2016 Jan; 11(1):21-6. PubMed ID: 26353076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.